Treatment of GIST Based on Specific Mutations

First-Line Treatment Algorithm by Mutation Type

The European Society for Medical Oncology recommends standard first-line therapy of imatinib 400 mg daily for KIT exon 11 mutations, with response rates of 50-67% and median progression-free survival exceeding 2 years 1, 3, 4
For KIT exon 9 mutations, the National Comprehensive Cancer Network suggests standard first-line treatment is imatinib 800 mg daily, which significantly improves progression-free survival compared to 400 mg daily 1, 2, 5
The American Society of Clinical Oncology states that PDGFRA D842V mutations should receive avapritinib 300 mg daily as first-line therapy, achieving >90% response rate with duration of response exceeding 70% at 1 year 1, 2
For wild-type GISTs, the European Society for Medical Oncology recommends considering molecular subtyping for SDH-deficiency, NF1-association, or NTRK/BRAF alterations, as these have specific treatment implications 2

The National Comprehensive Cancer Network recommends that for progression on imatinib 400 mg daily, the dose should be increased to 800 mg daily, except in mutation types known to be insensitive 1, 2, 7
The European Society for Medical Oncology suggests sunitinib as standard second-line therapy after imatinib failure or intolerance, administered at 50 mg daily for 4 weeks on/2 weeks off, or alternatively 37.5 mg continuously 1, 2, 6
The American Society of Clinical Oncology states that regorafenib 160 mg daily for 21 days of each 28-day cycle is standard third-line therapy after progression on both imatinib and sunitinib 1, 2, 5
For fourth-line treatment, the National Comprehensive Cancer Network recommends ripretinib 150 mg daily, which demonstrated significant progression-free survival improvement compared to placebo 2, 5

The European Society for Medical Oncology recommends adjuvant imatinib 400 mg daily for 3 years for significant risk of relapse, except in mutation types resistant to imatinib 1, 8, 2
For KIT exon 9 mutations, the American Society of Clinical Oncology suggests considering adjuvant imatinib 800 mg daily for 3 years 1
The National Comprehensive Cancer Network states that PDGFRA D842V-mutated GISTs should not receive adjuvant imatinib as they are resistant 1, 8

The European Society for Medical Oncology warns to never use imatinib for PDGFRA D842V mutations, as these require avapritinib 1, 2
The American Society of Clinical Oncology advises not to start KIT exon 9 mutations at 400 mg daily, as these require 800 mg from the outset for optimal outcomes 1, 5, 2
The National Comprehensive Cancer Network emphasizes the importance of performing mutational analysis before initiating therapy to guide appropriate drug selection and dosing 3, 1, 4